Hematology Workshop: Navigating Nonmalignant Diseases in Everyday Practice

8:30 AM - 1:20 PM EST

Overview

Community hematologists and oncologists carry the heavy burden of staying abreast of the most recent advancements in care across multiple hematologic diseases. These professionals also must recognize nonmalignant diseases that may be less common but that are equally important to diagnose and treat. Successful selection and implementation of testing methods are essential to provide a timely, accurate diagnosis of various rare diseases and may have a tremendous influence on treatment decisions and, ultimately, patient outcomes.

Using short, clinically-focused presentations and a question-and-answer sessions, this conference will enable learners to quickly master information on the diagnosis and treatment of various rare, noncancerous hematologic conditions, including hemolytic anemias, immune-mediated blood disorders, aplastic anemia, and microangiopathic disease.

Benefits of Attending

• Learn how to use targeted therapies for multiple hematologic disorders.
• Understand the concepts behind emerging therapies for hemolytic anemias.
• Acquire knowledge about immunosuppressive therapy for aplastic anemia.

Target Audience

This educational program is directed toward medical oncologists, hematologists, fellows, and other physicians involved in the treatment of hematologic diseases. Researchers, nurses, nurse practitioners, physician assistants, and other health care professionals are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Identify aspects and criteria key for the differential diagnosis and classification of nonmalignant hematologic disorders.
• Analyze the underlying pathobiology of benign blood diseases and how this has informed diagnostic confirmation and therapeutic development.
• Integrate emerging evidence on novel treatment strategies into practical management plans for benign blood disorders.
• Implement strategies to recognize, manage, and mitigate the impact of disease and treatment-related adverse events associated with treating benign blood disorders.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.